Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells

Larsulrik R. Nordstroem, Juan Sironi, Evelyn Aranda, Jorge Maisonet, Roman Perez-Soler, Peng Wu, Edward L. Schwartz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The autophagy inhibitors chloroquine (CQ) and hydroxychloroquine (HCQ) have single agent antiproliferative activity against human cancer cell lines; however, low potency may limit their antitumor efficacy clinically. We synthesized a series of chloroquine analogs that retained the 4-aminoquinoline subunit and incorporated different substituted triazoles into the target structure. These compounds were tested for growth inhibition against H460 and HCC827 human lung cancer and BxPC3 pancreatic cancer cells. The most potent compound, EAD1, had an IC50 of 5.8 μM in the BxPC3 cells and was approximately 8-fold more potent than CQ and HCQ. EAD1 inhibited autophagy, as judged by the cellular accumulation of the autophagy-related autophagosome proteins LC3-II and p62 and induced apoptosis. The increases in LC3-II levels by the analogues were highly correlated with their growth inhibitory IC50s, suggesting that autophagy blockade is closely linked to inhibition of cell proliferation. EAD1 is a viable lead compound for evaluation of the antitumor activity of autophagy inhibitors in vivo.

Original languageEnglish (US)
Pages (from-to)134-139
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume6
Issue number2
DOIs
StatePublished - Feb 12 2015

Fingerprint

Autophagy
Chloroquine
Pancreatic Neoplasms
Hydroxychloroquine
Lung Neoplasms
Cells
Lead compounds
Triazoles
Cell proliferation
Apoptosis
Growth
Human Activities
Inhibitory Concentration 50
Cell Proliferation
Proteins
Cell Line
Neoplasms

Keywords

  • Autophagy
  • chloroquinoline triazoles
  • click chemistry
  • lung cancer
  • pancreatic cancer

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells. / Nordstroem, Larsulrik R.; Sironi, Juan; Aranda, Evelyn; Maisonet, Jorge; Perez-Soler, Roman; Wu, Peng; Schwartz, Edward L.

In: ACS Medicinal Chemistry Letters, Vol. 6, No. 2, 12.02.2015, p. 134-139.

Research output: Contribution to journalArticle

@article{1fd100508c0d49ca9c4e38cae035a404,
title = "Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells",
abstract = "The autophagy inhibitors chloroquine (CQ) and hydroxychloroquine (HCQ) have single agent antiproliferative activity against human cancer cell lines; however, low potency may limit their antitumor efficacy clinically. We synthesized a series of chloroquine analogs that retained the 4-aminoquinoline subunit and incorporated different substituted triazoles into the target structure. These compounds were tested for growth inhibition against H460 and HCC827 human lung cancer and BxPC3 pancreatic cancer cells. The most potent compound, EAD1, had an IC50 of 5.8 μM in the BxPC3 cells and was approximately 8-fold more potent than CQ and HCQ. EAD1 inhibited autophagy, as judged by the cellular accumulation of the autophagy-related autophagosome proteins LC3-II and p62 and induced apoptosis. The increases in LC3-II levels by the analogues were highly correlated with their growth inhibitory IC50s, suggesting that autophagy blockade is closely linked to inhibition of cell proliferation. EAD1 is a viable lead compound for evaluation of the antitumor activity of autophagy inhibitors in vivo.",
keywords = "Autophagy, chloroquinoline triazoles, click chemistry, lung cancer, pancreatic cancer",
author = "Nordstroem, {Larsulrik R.} and Juan Sironi and Evelyn Aranda and Jorge Maisonet and Roman Perez-Soler and Peng Wu and Schwartz, {Edward L.}",
year = "2015",
month = "2",
day = "12",
doi = "10.1021/ml500348p",
language = "English (US)",
volume = "6",
pages = "134--139",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells

AU - Nordstroem, Larsulrik R.

AU - Sironi, Juan

AU - Aranda, Evelyn

AU - Maisonet, Jorge

AU - Perez-Soler, Roman

AU - Wu, Peng

AU - Schwartz, Edward L.

PY - 2015/2/12

Y1 - 2015/2/12

N2 - The autophagy inhibitors chloroquine (CQ) and hydroxychloroquine (HCQ) have single agent antiproliferative activity against human cancer cell lines; however, low potency may limit their antitumor efficacy clinically. We synthesized a series of chloroquine analogs that retained the 4-aminoquinoline subunit and incorporated different substituted triazoles into the target structure. These compounds were tested for growth inhibition against H460 and HCC827 human lung cancer and BxPC3 pancreatic cancer cells. The most potent compound, EAD1, had an IC50 of 5.8 μM in the BxPC3 cells and was approximately 8-fold more potent than CQ and HCQ. EAD1 inhibited autophagy, as judged by the cellular accumulation of the autophagy-related autophagosome proteins LC3-II and p62 and induced apoptosis. The increases in LC3-II levels by the analogues were highly correlated with their growth inhibitory IC50s, suggesting that autophagy blockade is closely linked to inhibition of cell proliferation. EAD1 is a viable lead compound for evaluation of the antitumor activity of autophagy inhibitors in vivo.

AB - The autophagy inhibitors chloroquine (CQ) and hydroxychloroquine (HCQ) have single agent antiproliferative activity against human cancer cell lines; however, low potency may limit their antitumor efficacy clinically. We synthesized a series of chloroquine analogs that retained the 4-aminoquinoline subunit and incorporated different substituted triazoles into the target structure. These compounds were tested for growth inhibition against H460 and HCC827 human lung cancer and BxPC3 pancreatic cancer cells. The most potent compound, EAD1, had an IC50 of 5.8 μM in the BxPC3 cells and was approximately 8-fold more potent than CQ and HCQ. EAD1 inhibited autophagy, as judged by the cellular accumulation of the autophagy-related autophagosome proteins LC3-II and p62 and induced apoptosis. The increases in LC3-II levels by the analogues were highly correlated with their growth inhibitory IC50s, suggesting that autophagy blockade is closely linked to inhibition of cell proliferation. EAD1 is a viable lead compound for evaluation of the antitumor activity of autophagy inhibitors in vivo.

KW - Autophagy

KW - chloroquinoline triazoles

KW - click chemistry

KW - lung cancer

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84922850049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922850049&partnerID=8YFLogxK

U2 - 10.1021/ml500348p

DO - 10.1021/ml500348p

M3 - Article

VL - 6

SP - 134

EP - 139

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 2

ER -